antigen stimulates dendritic cells (DCs) in vitro and is safe in vivo. B. bronchiseptica increases the expression of surface markers, the production of cytokines, and antigen-presenting capability of DCs. The survival rate of B. bronchiseptica-injected groups was 100% at 15 and 20 mg/kg doses, whereas that of LPS-injected groups was only 20%, 0% at 15 and 20 mg/kg doses respectively. These results indicate that B. bronchiseptica can be used as a safe adjuvant to enhance the antigen-presenting capability of DCs.
